HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Valentina Boni Selected Research

PM 01183

10/2023Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
1/2022Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.
11/2021Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
1/2021Effect of lurbinectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis.
12/2020Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
1/2020Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
1/2017Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Valentina Boni Research Topics

Disease

40Neoplasms (Cancer)
11/2023 - 08/2010
9Disease Progression
11/2023 - 01/2019
7Breast Neoplasms (Breast Cancer)
11/2023 - 10/2018
5Colorectal Neoplasms (Colorectal Cancer)
08/2012 - 08/2010
4Vomiting
04/2024 - 01/2017
4Endometrial Neoplasms (Endometrial Cancer)
11/2023 - 11/2021
4Fatigue
10/2023 - 01/2017
4Neoplasm Metastasis (Metastasis)
01/2022 - 02/2012
3Nausea
10/2023 - 01/2017
3Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2023 - 01/2020
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 01/2020
2Uterine Cervical Neoplasms (Cancer of the Cervix)
04/2024 - 10/2020
2Pneumonia (Pneumonitis)
04/2024 - 01/2021
2Triple Negative Breast Neoplasms
12/2023 - 01/2021
2Hypothyroidism
11/2023 - 01/2020
2Ovarian Neoplasms (Ovarian Cancer)
10/2023 - 01/2021
2Melanoma (Melanoma, Malignant)
08/2023 - 01/2020
2Diarrhea
01/2022 - 01/2020
2Neutropenia
01/2022 - 01/2021
2Dyspnea (Shortness of Breath)
01/2022 - 01/2021
2Exanthema (Rash)
01/2022 - 01/2020
2Colitis
01/2021 - 01/2020
2Carcinoma (Carcinomatosis)
11/2019 - 11/2011
1Syncope (Fainting)
04/2024
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
04/2024
1Arthralgia (Joint Pain)
11/2023
1Turcot syndrome
11/2023
1Constipation
10/2023
1Hyponatremia
01/2022
1Anemia
01/2022
1Microsatellite Instability
01/2022
1Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2022
1medullary Thyroid cancer
01/2022
1Central Nervous System Neoplasms
01/2022
1Abdominal Pain (Pain, Abdominal)
01/2022
1Ewing Sarcoma (Sarcoma, Ewing)
01/2022
1Squamous Cell Carcinoma of Head and Neck
10/2021
1Alopecia (Baldness)
01/2021
1Headache (Headaches)
01/2021

Drug/Important Bio-Agent (IBA)

7Immune Checkpoint InhibitorsIBA
01/2024 - 01/2020
7Biomarkers (Surrogate Marker)IBA
12/2023 - 08/2010
7PM 01183IBA
10/2023 - 01/2017
7Phosphotransferases (Kinase)IBA
06/2023 - 01/2018
4NivolumabIBA
04/2024 - 01/2017
4dostarlimabIBA
11/2023 - 01/2022
4PlatinumIBA
10/2023 - 10/2020
4Immunoconjugates (Immunoconjugate)IBA
01/2022 - 03/2020
4Peptide Hydrolases (Proteases)FDA Link
01/2021 - 01/2020
3Hormones (Hormone)IBA
11/2023 - 01/2019
3TropomyosinIBA
06/2023 - 01/2018
3ProdrugsIBA
01/2021 - 01/2020
3neratinibIBA
10/2020 - 10/2018
3MicroRNAs (MicroRNA)IBA
01/2012 - 08/2010
2IpilimumabIBA
04/2024 - 01/2021
2atezolizumabIBA
12/2023 - 01/2022
2Alanine Transaminase (SGPT)IBA
11/2023 - 10/2023
2Aspartate Aminotransferases (Aspartate Transaminase)IBA
10/2023 - 01/2021
2Transaminases (Aminotransferases)IBA
10/2023 - 01/2017
2selpercatinibIBA
01/2022 - 01/2022
2LigandsIBA
01/2022 - 01/2020
2Monoclonal AntibodiesIBA
01/2022 - 08/2012
2larotrectinibIBA
01/2022 - 01/2018
2Irinotecan (Camptosar)FDA LinkGeneric
01/2022 - 11/2011
2Ado-Trastuzumab EmtansineIBA
03/2020 - 01/2019
2Cetuximab (Erbitux)FDA Link
09/2019 - 08/2012
2ErbB Receptors (EGF Receptor)IBA
10/2018 - 08/2012
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2018 - 02/2012
1TransferasesIBA
04/2024
1Lipase (Acid Lipase)FDA Link
04/2024
1palbociclibIBA
01/2024
1taxaneIBA
12/2023
1ipatasertibIBA
12/2023
1130-nm albumin-bound paclitaxelIBA
12/2023
1Tumor Biomarkers (Tumor Markers)IBA
11/2023
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
11/2023
1Estrogen Receptor AntagonistsIBA
11/2023
1Estrogen ReceptorsIBA
11/2023
1giredestrantIBA
11/2023
1sotigalimabIBA
08/2023
1DNA (Deoxyribonucleic Acid)IBA
01/2023
1Cyclin-Dependent Kinase 9IBA
01/2022
1Alkaline PhosphataseIBA
01/2022
1Maytansine (Maitansine)IBA
01/2022
1emactuzumabIBA
01/2022
1ZirconiumIBA
01/2022
1EWS-FLI fusion proteinIBA
01/2022
1Transcription Factors (Transcription Factor)IBA
01/2022
1Doxorubicin (Adriamycin)FDA LinkGeneric
11/2021
1tipifarnib (R115777)IBA
10/2021
1Bevacizumab (Avastin)FDA Link
07/2021
1Programmed Cell Death 1 ReceptorIBA
01/2021
1cofetuzumab pelidotinIBA
01/2021
1monomethyl auristatin EIBA
01/2021
1Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2021
1CX-2029IBA
01/2021
1CTLA-4 AntigenIBA
01/2021
1Transferrin Receptors (Transferrin Receptor)IBA
01/2021
1Loperamide (Imodium)FDA LinkGeneric
10/2020

Therapy/Procedure

19Therapeutics
04/2024 - 08/2010
5Drug Therapy (Chemotherapy)
10/2023 - 01/2020